South Korea · Delayed Price · Currency is KRW PharmaResearch Statistics
Total Valuation
PharmaResearch has a market cap or net worth of KRW 3.06 trillion. The enterprise value is 2.68 trillion.
| Market Cap | 3.06T |
| Enterprise Value | 2.68T |
Important Dates
The next estimated earnings date is Friday, August 7, 2026.
| Earnings Date | Aug 7, 2026 |
| Ex-Dividend Date | Dec 29, 2025 |
Share Statistics
PharmaResearch has 10.39 million shares outstanding. The number of shares has increased by 11.63% in one year.
| Current Share Class | 10.39M |
| Shares Outstanding | 10.39M |
| Shares Change (YoY) | +11.63% |
| Shares Change (QoQ) | -3.10% |
| Owned by Insiders (%) | 35.02% |
| Owned by Institutions (%) | 16.62% |
| Float | 5.57M |
Valuation Ratios
The trailing PE ratio is 18.60 and the forward PE ratio is 16.99. PharmaResearch's PEG ratio is 0.77.
| PE Ratio | 18.60 |
| Forward PE | 16.99 |
| PS Ratio | 5.42 |
| PB Ratio | 4.18 |
| P/TBV Ratio | 4.60 |
| P/FCF Ratio | 20.45 |
| P/OCF Ratio | 17.13 |
| PEG Ratio | 0.77 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 11.37, with an EV/FCF ratio of 17.91.
| EV / Earnings | 15.21 |
| EV / Sales | 4.75 |
| EV / EBITDA | 11.37 |
| EV / EBIT | 12.21 |
| EV / FCF | 17.91 |
Financial Position
The company has a current ratio of 5.72, with a Debt / Equity ratio of 0.29.
| Current Ratio | 5.72 |
| Quick Ratio | 4.95 |
| Debt / Equity | 0.29 |
| Debt / EBITDA | 0.89 |
| Debt / FCF | 1.43 |
| Interest Coverage | 21.89 |
Financial Efficiency
Return on equity (ROE) is 27.26% and return on invested capital (ROIC) is 53.43%.
| Return on Equity (ROE) | 27.26% |
| Return on Assets (ROA) | 14.25% |
| Return on Invested Capital (ROIC) | 53.43% |
| Return on Capital Employed (ROCE) | 23.76% |
| Weighted Average Cost of Capital (WACC) | 6.60% |
| Revenue Per Employee | 1.04B |
| Profits Per Employee | 325.69M |
| Employee Count | 497 |
| Asset Turnover | 0.57 |
| Inventory Turnover | 1.80 |
Taxes
In the past 12 months, PharmaResearch has paid 57.61 billion in taxes.
| Income Tax | 57.61B |
| Effective Tax Rate | 24.15% |
Stock Price Statistics
The stock price has decreased by -31.95% in the last 52 weeks. The beta is 0.46, so PharmaResearch's price volatility has been lower than the market average.
| Beta (5Y) | 0.46 |
| 52-Week Price Change | -31.95% |
| 50-Day Moving Average | 305,070.00 |
| 200-Day Moving Average | 425,780.00 |
| Relative Strength Index (RSI) | 48.60 |
| Average Volume (20 Days) | 85,517 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, PharmaResearch had revenue of KRW 565.48 billion and earned 176.52 billion in profits. Earnings per share was 15,857.94.
| Revenue | 565.48B |
| Gross Profit | 438.70B |
| Operating Income | 225.17B |
| Pretax Income | 238.59B |
| Net Income | 176.52B |
| EBITDA | 241.40B |
| EBIT | 225.17B |
| Earnings Per Share (EPS) | 15,857.94 |
Balance Sheet
The company has 630.78 billion in cash and 213.75 billion in debt, with a net cash position of 417.03 billion or 40,138.52 per share.
| Cash & Cash Equivalents | 630.78B |
| Total Debt | 213.75B |
| Net Cash | 417.03B |
| Net Cash Per Share | 40,138.52 |
| Equity (Book Value) | 733.17B |
| Book Value Per Share | 67,076.36 |
| Working Capital | 650.20B |
Cash Flow
In the last 12 months, operating cash flow was 178.90 billion and capital expenditures -29.00 billion, giving a free cash flow of 149.91 billion.
| Operating Cash Flow | 178.90B |
| Capital Expenditures | -29.00B |
| Depreciation & Amortization | 16.23B |
| Net Borrowing | -6.35B |
| Free Cash Flow | 149.91B |
| FCF Per Share | 14,428.53 |
Margins
Gross margin is 77.58%, with operating and profit margins of 39.82% and 31.22%.
| Gross Margin | 77.58% |
| Operating Margin | 39.82% |
| Pretax Margin | 42.19% |
| Profit Margin | 31.22% |
| EBITDA Margin | 42.69% |
| EBIT Margin | 39.82% |
| FCF Margin | 26.51% |
Dividends & Yields
This stock pays an annual dividend of 3,700.00, which amounts to a dividend yield of 1.22%.
| Dividend Per Share | 3,700.00 |
| Dividend Yield | 1.22% |
| Dividend Growth (YoY) | 236.36% |
| Years of Dividend Growth | 6 |
| Payout Ratio | 6.64% |
| Buyback Yield | -11.63% |
| Shareholder Yield | -10.35% |
| Earnings Yield | 5.76% |
| FCF Yield | 4.89% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for PharmaResearch is 516,214.29, which is 74.99% higher than the current price. The consensus rating is "Buy".
| Price Target | 516,214.29 |
| Price Target Difference | 74.99% |
| Analyst Consensus | Buy |
| Analyst Count | 14 |
| Revenue Growth Forecast (3Y) | 21.06% |
| EPS Growth Forecast (3Y) | 22.79% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
PharmaResearch has an Altman Z-Score of 10.88 and a Piotroski F-Score of 6.
| Altman Z-Score | 10.88 |
| Piotroski F-Score | 6 |